Eruption of Indonesia's Mt Ibu Forces 7 Villages to Evacuate

Lightning appears amid a storm as Mount Ibu spews volcanic material during an eruption, as seen from Gam Ici in West Halmahera, North Maluku province, Indonesia, May 18, 2024 in this handout image. The Center for Volcanology and Geological Hazard Mitigation (PVMBG)/Handout via REUTERS
Lightning appears amid a storm as Mount Ibu spews volcanic material during an eruption, as seen from Gam Ici in West Halmahera, North Maluku province, Indonesia, May 18, 2024 in this handout image. The Center for Volcanology and Geological Hazard Mitigation (PVMBG)/Handout via REUTERS
TT

Eruption of Indonesia's Mt Ibu Forces 7 Villages to Evacuate

Lightning appears amid a storm as Mount Ibu spews volcanic material during an eruption, as seen from Gam Ici in West Halmahera, North Maluku province, Indonesia, May 18, 2024 in this handout image. The Center for Volcanology and Geological Hazard Mitigation (PVMBG)/Handout via REUTERS
Lightning appears amid a storm as Mount Ibu spews volcanic material during an eruption, as seen from Gam Ici in West Halmahera, North Maluku province, Indonesia, May 18, 2024 in this handout image. The Center for Volcanology and Geological Hazard Mitigation (PVMBG)/Handout via REUTERS

A volcano on the remote Indonesian island of Halmahera has spectacularly erupted, spewing a grey ash cloud into the sky, and people from seven nearby villages have been evacuated, authorities said on Sunday.
Mt. Ibu erupted on Saturday evening, sending ash 4 km (2.5 miles) high, as streaks of purple lightning flashed around its crater, according to information and images shared by Indonesia's volcanology agency.
A joint team comprised of police, military and search and rescue officials was dispatched to the area to evacuate residents from surrounding villages, Abdul Muhari, from the disaster mitigation agency, said in a statement.
According to Reuters, photos shared by the disaster agency showed authorities assisting the elderly, while other residents were moved in pick-up trucks and accommodated in emergency tents for the night.
The agency did not provide any information about how many people had been moved, but authorities have recommended that a seven-km (4.35-mile) radius be cleared.
Indonesia's volcanology agency raised the alert level of the volcano to the highest level on Thursday, after Ibu erupted multiple times earlier this month.
Ibu's activities follow a series of eruptions of different volcanoes in Indonesia, which sits on the Pacific "Ring of Fire" and has 127 active volcanoes.
Flash floods and cold lava flow from Mount Marapi, one of the most active in West Sumatra province, covered several nearby districts following torrential rain on May 11, killing more than 60 people.
In recent weeks, North Sulawesi's Ruang volcano has also erupted, spewing incandescent lava. The eruption prompted authorities to evacuate more than 12,000 people on a nearby island.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”